Last reviewed · How we verify
Turimycin A5 (JOSAMYCIN)
Turimycin A5 (generic name: JOSAMYCIN) is a josamycin drug. It is currently in Phase 3 development.
JOSAMYCIN works by binding to the bacterial ribosome and inhibiting the production of essential proteins.
Turimycin A5, also known as JOSAMYCIN, is a small molecule antibiotic belonging to the josamycin class. It is a macrolide antibiotic that works by inhibiting protein synthesis in bacteria, ultimately leading to bacterial cell death. However, its target and exact mechanism of action are unknown. JOSAMYCIN is not approved by the FDA for any indications, and its commercial status, including patent and generic availability, is unclear. Further research is needed to determine its safety and efficacy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | JOSAMYCIN |
|---|---|
| Drug class | josamycin |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Imagine your body's cells are like factories that make proteins to keep you healthy. JOSAMYCIN is like a special tool that blocks the factory's machinery, preventing the bacteria from making the proteins they need to survive. This ultimately leads to the death of the bacterial cells.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Turimycin A5 CI brief — competitive landscape report
- Turimycin A5 updates RSS · CI watch RSS
Frequently asked questions about Turimycin A5
What is Turimycin A5?
How does Turimycin A5 work?
What is the generic name of Turimycin A5?
What drug class is Turimycin A5 in?
What development phase is Turimycin A5 in?
Related
- Drug class: All josamycin drugs
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing